Afelimomab
Afelimomab (MAK 195F) is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.[1][2]
Monoclonal antibody | |
---|---|
Type | F(ab')2 fragment |
Source | Mouse |
Target | TNFα |
Clinical data | |
ATC code | |
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG | |
|
References
- Rondon, E.; Venkataraman, R. (2005). "Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels". Critical Care. 9 (5): E20. doi:10.1186/cc3798. PMC 1297624. PMID 16277704.
- Panacek, E. A.; Marshall, J. C.; Albertson, T. E.; Johnson, D. H.; Johnson, S.; MacArthur, R. D.; Miller, M.; Barchuk, W. T.; Fischkoff, S.; Kaul, M.; Teoh, L.; Van Meter, L.; Daum, L.; Lemeshow, S.; Hicklin, G.; Doig, C.; Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators (2004). "Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels". Critical Care Medicine. 32 (11): 2173–2182. doi:10.1097/01.CCM.0000145229.59014.6C. PMID 15640628.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.